contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

LIDDS är ett läkemedelsbolag. Bolaget utvecklar läkemedelsprodukter baserade på en patentskyddad och kliniskt testad drug delivery-teknologi. Egenskaperna hos produkterna utgör grunden för LIDDS teknologiplattform för utveckling av injicerbara läkemedelsprodukter. LIDDS är förkortningen för Local Intelligent Drug Delivery System, och bolaget har sitt huvudkontor i Uppsala.

LIDDS

October - DecemberNet sales amounted to 0 MSEKThe operating result for the period was -1.1 MSEKThe net result was -1.0 MSEK corresponding to earnings per share of SEK -0.01Cash flow from operating...

<div class="mfn-body">October - December<ul><li>Net sales amounted to 0 MSEK</li><li>The operating result for the period was -1.1 MSEK</li><li>The net result was -1.0 MSEK corresponding to earnings per share of SEK -0.01</li><li>Cash flow from operating activities amounted to -1.0 MSEK</li><li>Cash and cash equivalents amounted to 5.5 MSEK</li></ul>January – December<ul><li>Net sales amounted to 0 MSEK</li><li>The operating result for the period was -4.5 MSEK</li><li>The net result was -4.3 MSEK corresponding to earnings per share of SEK -0.04</li><li>Cash flow from operating activities amounted to -5.4 MSEK</li></ul>Significant events 2024<ul><li>On the Extraordinary General Meeting of shareholders on the 9 January 2024 Daniel Lifveredson, Torbjörn Browall and Lars-Inge Sjöqvist were elected new members of the Board.</li><li>In January it was announced that an agreement to acquire Noviga Research AB had been signed.</li><li>In May, Mats Wiking was appointed new CEO from 1 September 2024. </li></ul>CEO StatementIn accordance with previous decisions, LIDDS has continued to realize the cost savings which has been possible to implement without affecting the underlying assets that the company has. The goal for the fourth quarter was to try to get some form of financing or other solution for one or more of the three clinical projects that we are focusing on. LIDDS has not yet been able to achieve any success in these discussions with external parties. In order for LIDDS to be able to carry out clinical projects under its own management (where Nanodotax and Nanoimod are almost ready), significant capital contributions are required. For Noviga, capital is also required to be able to carry out a tox study, which would probably take LIDDS to a higher valuation. Even though the financial markets have started to show improvement, LIDDS continues to assess that it is not in the best interest for the shareholders to try to raise capital thru the market, considering the company's current valuation. The current focus is to find external party/parties that can realize and execute the above-mentioned projects, and we are actively working to find such a solution for one or more of the projects. With LIDDS current cash and cost structure, the company believes that we have the endurance to find the best possible arrangement for its shareholders. Mats Wiking CEO and CFOThe interim report is available on the company’s website <a rel="noopener" href="https://liddspharma.com/sv/investerare/finansiella-rapporter/">https://liddspharma.com/sv/investerare/finansiella-rapporter/</a></div><div class="mfn-footer mfn-contacts mfn-cb73eb895ad4">For additional information, please contact<hr>Mats Wiking, CEO and CFO Phone: +46 (0)70 620 04 00 E-mail: mats.wiking<a rel="noopener" href="mailto:jenni.bjornulfson@liddspharma.com">@liddspharma.com</a>LIDDS’ Certified Adviser is Redeye AB</div><div class="mfn-footer mfn-about mfn-dcb9e4cb41ff">LIDDS in brief:<hr>LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/bb043d91-b969-4e4c-829e-5ee463335697/year-end-report-2024.pdf" class="mfn-primary">Year End Report 2024</a></div>